Sanofi SA/ FR0000120578 /

8/16/2022 12:33:23 PM	Chg. +1.53	Volume	Bid12:33:24 PM	Ask12:33:23 PM	Market Capitalization	Dividend Y.	P/E Ratio
86.65EUR	+1.80%	603,178 Turnover: 52.43 mill.	86.65Bid Size: 19	86.66Ask Size: 27	109.09 bill.EUR	3.82%	17.53

TeleTrader 8/11 GSK falls 12% on worries over Zantac litigation

TeleTrader 7/28 Sanofi's Q2 sales up by 15.7% to €10.12B

TeleTrader 6/24 Sanofi: COVID shot has 72% Omicron efficacy

TeleTrader 6/2 Regeneron to buy Sanofi's stake in joint project for $900M

TeleTrader 4/28 Sanofi's revenue rises 12.6% to €9.7B in Q1

TeleTrader 3/30 EMA begins reviewing Sanofi-GSK COVID-19 vaccine

GlobeNewswire 3/30 Press Release: Availability of the Q1 2022 Memorandum for modelling purposes

GlobeNewswire 3/29 IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate...

GlobeNewswire 3/29 IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement ...

GlobeNewswire 3/29 Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology ...

GlobeNewswire 3/29 Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilum...

GlobeNewswire 3/28 Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indica...

GlobeNewswire 3/26 Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly impro...

GlobeNewswire 3/18 Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris

GlobeNewswire 3/16 Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel ...

GlobeNewswire 3/15 Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative t...

GlobeNewswire 3/14 Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic ...

GlobeNewswire 3/9 Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonst...

GlobeNewswire 3/8 Sanofi recognized by S&P as one of the most sustainability-committed companies

GlobeNewswire 3/3 Nirsevimab significantly protected infants against RSV disease in Phase 3 trial

GlobeNewswire 3/2 Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology ...

GlobeNewswire 2/28 Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corpor...

GlobeNewswire 2/26 Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved si...

GlobeNewswire 2/26 Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly red...

TeleTrader 2/23 Sanofi, GSK to ask for COVID-19 vaccine authorization